The potential role of natriuretic peptides and other biomarkers in heart failure diagnosis, prognosis and management

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 9, 2015, Pages 1017-1030

  Ibrahim, Nasrien ^a   Januzzi, James L ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

biomarkers; heart failure; natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; SERELAXIN; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; CARDIAC RESYNCHRONIZATION THERAPY; DIAGNOSTIC VALUE; HEART FAILURE; HUMAN; OBESITY; PROGNOSIS; REVIEW; BLOOD;

BIOMARKERS; HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 84940477951     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1071664     Document Type: Review

References (94)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 2013; 127: e6-e245
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011;123(8):933-44
3. Green SM, Martinez-Rumayor A, Gregory SA, et al. Clinical uncertainty, diagnostic accuracy, and outcomes in emergency department patients presenting with dyspnea. Arch Intern Med 2008;168: 741-8
4. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;52(7):534-40
5. van Kimmenade RR, Januzzi JL Jr. Emerging biomarkers in heart failure. Clin Chem 2012;58:127-38
6. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147-239
7. de Bold AJ, de Bold ML. Determinants of natriuretic peptide production by the heart: basic and clinical implications. J Investig Med 2005;53(7):371-7
8. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994;90:195-203
9. Vodovar N, Seronde MF, Laribi S, et al. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J 2014, 35(48):3434-41
10. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol 2007; 49(10): 1071-8
11. van Kimmenade RR, Januzzi JL Jr, Bakker JA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009;53:884-90
12. Federico C. Natriuretic peptide system and cardiovascular disease. Heart Views 2010; 11(1):10-15
13. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. American Journal of Physiology - Regulatory. Integrative and Comparative Physiology 2007;292(2): R897-901
14. Boerrigter G, Costello-Boerrigter LC, Harty GJ, et al. B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. Am J Physiol Regul Integr Comp Physiol 2009;296(6): R1744-50
15. Hawkridge AM, Heublein DM, Bergen HR III, et al. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP- 32) in severe human heart failure. 2005; 102(48):17442-7
16. Miller WL, Phelps MA, Wood CM, et al. Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure. Circ Heart Fail 2011;4:355-60
17. McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371(11):993-1004
18. Packer M, McMurray JJ, Desai AS, et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2014;131(1): 54-61
19. Doust J, Lehman R, Glasziou The role of BNP testing in heart failure. Am Fam Physician 2006;74(11):1893-900
20. Kim HN, Januzzi JL Jr. Natriuretic peptide testing in heart failure. Circulation 2011;123:2015-19
21. Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004;6(3):295-300
22. Knudsen CW, Omland T, Clopton P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspneic patients: an analysis from the breathing not properly multinational study. J Am Coll Cardiol 2005;46(5):838-44
23. Baggish AL, van Kimmenade RR, Januzzi JL. Jr. The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. Am J Cardiol 2008;101(3):S43-8
24. van Kimmenade RR, Januzzi JL Jr, Bakker JA, et al. Renal clearance of B-type natriuretic peptide and amino terminal pro-B-type natriuretic peptide a mechanistic study in hypertensive subjects. J Am Coll Cardiol 2009;53(10):884-90
25. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003;41(3):571-9
26. Chenevier-Gobeaux C, Claessens YE, Voyer S, et al. Influence of renal function on N-terminal pro-brain natriuretic peptide (NT-proBNP) in patients admitted for dyspnoea in the Emergency Department: comparison with brain natriuretic peptide (BNP). Clin Chim Acta 2005;361(1-2): 167-75
27. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004;164(20):2247-52
28. Krauser DG, Lloyd-Jones DM, Chae CU, et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. Am Heart J 2005;149(4):744-50
29. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing not properly multinational study investigators. rapid measurement of b-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7
30. Januzzi JL Jr, Camargo CA, Anwaruddin S, et al. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95(8):948-54
31. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: the International Collaborative of NT-proBNP Study. Eur Heart J 2006;27(3):330-337
32. Kucher N, Printzen G, Goldhaber SZ. Prognostic role of brain natriuretic peptide in acute pulmonary embolism. Circulation 2003;107(20):2545-7
33. van Kimmenade RR, Pinto YM, Januzzi JL Jr. Importance and interpretation of intermediate (gray zone) amino-terminal pro-B-type natriuretic peptide concentrations. Am J Cardiol 2008; 101(3A):39-42
34. Steinhart B, Thorpe KE, Bayoumi AM, et al. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009;54(16):1515-21
35. Steinhart B, Thorpe KE, Bayoumi AM, et al. Improving the diagnosis of acute heart failure using a validated prediction model. J Am Coll Cardiol 2009;54(16):1515-21
36. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004;44(6): 1328-33
37. Maisel A, Mueller C, Nowak R, et al. Midregion pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol 2010;55: 2062-76
38. Rehman SU, Martinez-Rumayor A, Mueller T, Januzzi JL Jr. Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study. Clin Chim Acta 2008;392(1-2):41-5
39. Salah K, Kok WE, Eurlings LW, et al. A novel discharge risk model for patients hospitalised for acute decompensated heart failure incorporating N-terminal pro-B-type natriuretic peptide levels: a European coLlaboration on Acute decompeNsated Heart Failure: ELAN-HF Score. Heart 2014;100(2):115-25
40. Valle R, Aspromonte N, Feola M. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function. J Card Fail 2005;11(7):498-503
41. Booth RA, Hill SA, Don-Wauchope A, et al. Performance of BNP and NT-proBNP for diagnosis of heart failure in primary care patients: a systematic review. Heart Fail Rev 2014;18(4):439-51
42. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 2005;330:625
43. Masson S, Latini R, Anand IS, et al. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in val-HeFT (valsartan heart failure trial). J Am Coll Cardiol 2008;52(12):997-1003
44. van Veldhuisen. DJ, Linssen GM, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol 2013;61(14):1498-506
45. Komajda M, Carson PE, Hetzel S, et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011;4:27-35
46. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350(7):655-63
47. McKie PM, Cataliotti A, Lahr BD, et al. The prognostic value of n-terminal pro-Btype natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. J Am Coll Cardiol 2010;55(19):2140-7
48. Nadir MA, Gandy S, Ireland S, et al. An increased B-type natriuretic peptide in the absence of a cardiac abnormality identifies those whose left ventricular mass will increase over time. JCHF 2015;3(1):87-93
49. Seliger SL, de Lemos J, Neeland IJ, et al. Older adults, "Malignant" left ventricular hypertrophy, and associated cardiac-specific biomarker phenotypes to identify the differential risk of new-onset reduced versus preserved ejection fraction heart failure: CHS (cardiovascular health study). JCHF 2015;3(6):445-55
50. Gaggin HK, Januzzi JL Jr. Natriuretic peptides in heart failure and acute coronary syndrome. Clin Lab Med 2014;34(1):43-58
51. Kindermann I, Barth C, Mahfoud F, et al. Update on Myocarditis. J Am Coll Cardiol 2012;59(9):779-92
52. Banypersad SM, Moon JC, Whelan C, et al. Updates in cardiac amyloidosis: a review. J Am Heart Assoc 2012;1:e000364
53. Wu AH, Johnson ML, Aaronson KD, et al. Brain natriuretic peptide predicts serious cardiac allograft rejection independent of hemodynamic measurements. J Heart Lung Transplant 2005;24:52-7
54. Akashi YJ, Goldstein DS, Barbara G, et al. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation 2008;118(25):2754-62
55. Parikh V, Kim C, Siegel RJ, et al. Natriuretic peptides for risk stratification of patients with valvular aortic stenosis. Circ Heart Fail 2015;373-80
56. Ky B, Putt M, Sawaya H, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol 2014;63; 809-16
57. Martinez-Selles M. B-type natriuretic peptide in the evaluation of acute dyspnea. N Engl J Med 2004;350:2416-17
58. Moe GW, Howlett J, Januzzi JL. N-terminal pro-B-type natriuretic peptide testing improves the management of patients with suspected acute heart failure: primary results of the Canadian prospective randomized multicenter IMPROVE-CHF study. Circulation 2007;115:3103-10
59. Motiwala SR, Januzzi JL Jr. The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure. Clin Pharmacol Ther 2013;93(1): 57-67
60. Troughton R, Felker GM, Januzzi JL. Natriuretic peptide-guided heart failure management. Eur Heart J 2014;35(1):16-24
61. Januzzi JL Jr, Rehman SU, Mohammed AA, et al. Use of amino-terminal pro-B type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. J Am Coll Cardiol 2011;58:1881-9
62. Bhardwaj A, Rehman SU, Mohammed A. Design and methods of the Pro-B type natriuretic peptide outpatient tailored chronic heart failure therapy (PROTECT) study. Am Heart J 2010;159:532-8
63. Weiner RB, Baggish AL, Chen-Tournoux A, et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides: mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study. Eur J Heart Fail 2013;15:342-51
64. Gaggin HK, Mohammed AA, Bhardwaj A, et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly: results from the Prospective, Randomized ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. J Card Fail 2012;18: 626-34
65. Savarese G, Trimarco B, Dellegrottaglie S, et al. Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials. PLoS ONE 2013;8:e58287
66. Felker G, Ahmad T, Anstrom KJ, et al. Rationale and design of the GUIDE-IT study: guiding evidence based therapy using biomarker intensified treatment in heart failure. JCHF 2014;2(5):457-65
67. Maisel A, Barnard D, Jaski B, et al. Primary results of the HABIT trial (heart failure assessment with BNP in the home). J Am Coll Cardiol 2013;61(16):1726-35
68. Januzzi JL. Natriuretic peptides, ejection fraction, and prognosis: parsing the phenotypes of heart failure. J Am Coll Cardiol 2013;61(14):1507-9
69. Haass M, Kitzman DW, Anand IS, et al. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction (I-PRESERVE) Trial. Circ Heart Fail 2011;4:324-31
70. Cleland JGF, Tendera M, Adamus J, et al. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006;27:2338-45
71. Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370:1383-92
72. Ledwidge M, Gallagher J, Conlon C, et al. Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial. JAMA 2013; 310(1):66-74
73. Huelsmann M, Neuhold S, Resl M, et al. Pontiac (NT-proBNP selected prevention of cardiac events in a population of diabetic patients without a history of cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013; 62(15):1365-72
74. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002;106:2961-6
75. Ho JE, Larson MG, Ghorbani A, et al. Soluble ST2 predicts elevated SBP in the community. J Hypertens 2013;31(7):1431-6 .discussion 1436
76. Coglianese EE, Larson MG, Vasan RS, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012;58(12):1673-81
77. Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol 2007;50:607-13
78. Manzano-Fernández S, Mueller T, Pascual-Figal D, et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011;107(2):259-67
79. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail 2008;14(9):732-8
80. Zilinski JL, Shah RV, Gaggin HK, et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 2012;16(4):R135
81. Maisel A, Xue Y, van Veldhuisen DJ, et al. Effect of spironolactone on 30-day death and heart failure rehospitalization (from the COACH Study). Am J Cardiol 2014;114: 737-42
82. Gaggin HK, Szymonifka J, Bhardwaj A, et al. Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure. JCHF 2014;2(1):65-72
83. Anand IS, Rector TS, Kuskowski M, et al. Prognostic value of soluble ST2 in the Valsartan Heart Failure Trial. Circ Heart Fail 2014;7:418-26
84. Piper S, Hipperson D, deCourcey J, et al. Biological variability of soluble st2 in stable chronic heart failure. Heart 2014;100:A29
85. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial infarction. Eur Heart J 2012;33:2551-67
86. Pascual-Figal DA, Casas T, Ordonez-Llanos J, et al. Highly sensitive troponin T for risk stratification of acutely destabilized heart failure. Am Heart J 2012; 163(6):1002-10
87. Parissis JT, Papadakis J, Kadoglou NP, et al. Prognostic value of high sensitivity troponin T in patients with acutely decompensated heart failure and non-detectable conventional troponin T levels. Int J Cardiol 2013;168(4):3609-12
88. Masson S, Anand I, Favero C, et al. Serial measurement of cardiac troponin T using a highly sensitive assay in patients with chronic heart failure: data from 2 large randomized clinical trials. Circulation 2012;125:280-8
89. Manzano-Fernandez S, Januzzi JL Jr, Boronat-Garcia M, et al. Beta-trace protein and cystatin C as predictors of long-term outcomes in patients with acute heart failure. J Am Coll Cardiol 2011;57(7): 849-58
90. Shrestha K, Shao Z, Singh D, et al. Relation of systemic and urinary neutrophil gelatinase-associated lipocalin levels to different aspects of impaired renal function in patients with acute decompensated heart failure. Am J Cardiol 2012;110(9):1329-35
91. Maisel AS, Mueller C, Fitzgerald R, et al. Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. Eur J Heart Fail 2011;13(8):846-51
92. De Berardinis B, Magrini L, Zampini G, et al. Usefulness of combining galectin-3 and BIVA assessments in predicting short- and long-term events in patients admitted for acute heart failure. Biomed Res Int 2014;2014:983098
93. Jungbauer CG, Birner C, Jung B, et al. Kidney injury molecule-1 and N-acetylbeta- D-glucosaminidase in chronic heart failure: possible biomarkers of cardiorenal syndrome. Eur J Heart Fail 2011;13(10): 1104-10
94. Meersch M, Schmidt C, Van Aken H, et al. Urinary TIMP-2 and IGFBP7 as early biomarkers of acute kidney injury and renal recovery following cardiac surgery. PLoS one 2014;9(3):e93460